Clinical course of myelopathy
| Symptoms at presentationa | Paresthesia lower limbs: 6/10 (60%) |
| Pain (back and legs): 5/10 (50%) | |
| Lower extremity motor weakness: 7/10 (70%) | |
| Urinary incontinence: 4/10 (40%) | |
| Bowel incontinence: 2/10 (20%) | |
| Treatment received | Steroids: 9 |
| IvIg: 1 | |
| Hyperbaric oxygen: 2 | |
| Plasmapheresis: 2 | |
| Bevacizumab (Avastin): 1 | |
| Mean duration of clinical follow-up (mo) | 22 (range: 4–162) |
| Clinical course on follow-up (available in 7 patients) | Improved with some sequelae: 5 |
| Progressive: 2 | |
| Resolved: 0 |
Note:—IvIg indicates intravenous immunoglobulin.
↵a Detailed clinical examination was not available for 1 patient. Hence, only 10 patients were included for evaluation of the clinical course.